News

Stay Up-To-Date on NEXT Oncology

Dr. David Sommerhalder Named 2025 San Antonio Business Journal Health Care Hero

We are so proud that Dr. David Sommerhalder has been selected as a 2025 Health Care Hero in the Medical Research Category by the San Antonio Business Journal. Read more ...

Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors

ALTA3263 is a potential best-in-class KRAS-selective small molecule inhibitor that potently targets >90% of KRAS mutations. Read More

Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins

Designed with Iambic’s AI-Drug Discovery platform, IAM1363 is highly differentiated by its target selectivity, brain-penetrance, pan-mutant activity, and tumor enrichment. Read More

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate

Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced initiation of a Phase 1/2 clinical study of its potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate, AVZO-1418, ...

NEXT Oncology Names Dr. Alex Spira Chief Scientific Officer

Dr. Spira to lead scientific and research strategy, advancing Phase 1 oncology trials. SAN ANTONIO, TX – May 20, 2025 – NEXT Oncology, one of the world’s largest Phase 1 ...

Crown Bioscience and NEXT Oncology Cement Partnership Extension

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, is pleased to announce the extension of ...

Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer

Tagworks Pharmaceuticals BV (“Tagworks”), a clinical-stage precision oncology company using its proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors, today announced ...

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing. Read More

NEXT Oncology Opens Newest Phase 1 Clinical Trial Center in Houston, Texas

With continued global expansion plans, NEXT Oncology is one of the largest Phase 1 Cancer Trial organizations in the world. (SAN ANTONIO, TX) March 25, 2025 ––NEXT Oncology has opened ...

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4. Read More